NCT06381232 Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population
| NCT ID | NCT06381232 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Viome |
| Condition | General Health |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2018-07-23 |
| Primary Completion | 2028-07-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2018-07-23 with a primary completion date of 2028-07-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with health and disease.
Eligibility Criteria
Inclusion Criteria: * Anyone that resides in the US at the time of enrollment. Exclusion Criteria: * None
Contact & Investigator
Momchilo Vuyisich, PhD
PRINCIPAL INVESTIGATOR
Viome
Frequently Asked Questions
Who can join the NCT06381232 clinical trial?
This trial is open to participants of all sexes, studying General Health. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06381232 currently recruiting?
Yes, NCT06381232 is actively recruiting participants. Contact the research team at studies@viome.com for enrollment information.
Where is the NCT06381232 trial being conducted?
This trial is being conducted at Bothell, United States.
Who is sponsoring the NCT06381232 clinical trial?
NCT06381232 is sponsored by Viome. The principal investigator is Momchilo Vuyisich, PhD at Viome. The trial plans to enroll 20,000 participants.